Gilead Doesn’t Push Limits In Pricing Its New Lymphoma Drug Zydelig
This article was originally published in The Pink Sheet Daily
Executive Summary
Facing pressure over the price of its hep C treatment Sovaldi, Gilead’s patient assistance program potentially knocks down the monthly copay to $5 for its newly approved idelalisib.